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A chronic wound is a wound that is delayed in one of the wound-healing stages and cannot progress any further. A chronic
wound leaves the patient at risk of infection and hospitalization. In these case series, 16 patients affected by venous ulcers
underwent Hyalomatrix PA grafting for reconstructive surgery. Hyalomatrix PA is a bilayered, sterile, flexible, and conformable
three-dimensional matrix made of fibers of HYAFF, a benzyl ester of hyaluronic acid, and a semipermeable silicone membrane.
Hyalomatrix PA acts as a substitutive and regenerative permanent matrix able to replace the dermis providing a three-dimensional
matrix for cellular invasion and capillary growth.The silicon layer controls water vapor loss avoiding an excessive loss of fluids and
acts as a semipermeable barrier to the external agents. In the presented cases, the average area grafted per procedure was 153 cm2.
The length of followup ranged from 0.5 to 1 year. The final results were considered to be good in 12 cases, fair in 3 cases, and poor
in one case. This study suggests that the combination of wound bed preparation with application of the hyaluronic regenerative
matrix can be a valid approach for treatment of partial thickness ulcers.
1. Introduction
Chronic wound is a wound that does not heal in an orderly
set of stages and in a predictable amount of time the waymost
wounds do; wounds that do not heal within three months
are often considered chronic. Chronic wounds seem to be
detained in one or more of the phases of wound healing. For
example, chronic wounds often remain in the inflammation
stage for too long.Many conditions are associatedwith abnor-
mal cutaneouswound healing, and several examples illustrate
the multifactorial nature of these condition. Examples are
“trapping” of growth factors [1]; blood share alterations and
prothrombotic factors response [2]; abnormalities in cell
migration and proliferation [3]; persistence in inflammatory
phase and secretion of inflammatory cytokines that are
responsible of a long-lasting flogistic condition in the wound
[4, 5]; synthesis and secretion of extracellular matrix proteins
and cytokines [6]; phenotypical cellular alterations [7].
Several studies concerning wound physiopathology can
confirm each of these hypothesis, and particularly the per-
sistence of inflammation is probably the most important
factor that leads a wound into a steady, chronic condition of
nonhealing.
Venous ulcers are wounds that are thought to occur due
to improper functioning of venous valves, usually of the legs.
They are the major cause of chronic wounds, occurring in
70% to 90% of chronic lesions [8].
The treatment of venous ulcers is mostly based on the
employment of advanced wound care dressings, regenerative
matrices, dermal substitutes, and skin grafts. In the last
few years dermal substitutes and regenerative matrices have
been developed to treat different kinds of ulcers. Dermal
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Table 1: Patients treated with Hyalomatrix PA: description and area of ulcers, complications, and results.
Patient Age Sex Indication Grafted area cm2 Complication Results
1 74 M Venous ulcer 175 None Good
2 83 M Venous ulcer 205 None Good
3 88 M Venous ulcer 125 None Fair
4 80 F Venous ulcer 275 None Good
5 82 M Venous ulcer 150 None Good
6 64 F Venous ulcer 185 None Good
7 80 F Venous ulcer 125 None Good
8 73 F Venous ulcer 170 Infection underHyalomatrix Fair
9 78 F Venous ulcer 145 None Good
10 73 M Venous ulcer 175 None Good





12 77 M Venous ulcer 135 None Fair
13 86 M Venous ulcer 55 None Good
14 76 F Venous ulcer 95 None Good
15 74 F Venous ulcer 125 None Good
16 75 M Venous ulcer 150 None Good
substitutes and regenerative matrices are a major topic of
concern for the surgeon and staff involved in the man-
agement and closure of vascular ulcers. There have been
two major approaches to the provision of a cell-free matrix
for replacement of the dermal component of skin: the first
one is to fabricate a matrix with the required physical and
chemical structure; the second approach envisages the use of
decellularized allogenic human skin.
Benzyl esters of hyaluronic acid (HYAFF) have been
extensively studied in the field of tissue engineering and
as wound dressings [9, 10], as such hyaluronic acid deriva-
tives show different degradation profiles. Hyalomatrix PA
(“prolonged action,” Anika Therapeutics Srl, Abano Terme,
Italy) is a nonwoven pad composed of HYAFF, the total
ester derivative of hyaluronic acid, physically coupled with
a layer of medical grade silicone that controls water vapor
loss avoiding an excessive loss of fluids, and acts as a semi-
permeable barrier to the external agents. It is a sterile, single
use, flexible, and conformable wound dressing which acts as
a dermal substitute to replace the dermis, providing a three-
dimensionalmatrix for cellular invasion and capillary growth
[11–13].
2. Patients and Methods
Between January 2009 and January 2010, 16 patients (7 males
and 9 females) from two different hospitals (Department of
Dermatology of Macchi Foundation Hospital, Varese, and
Zucchi Clinical Institute, Monza) underwent Hyalomatrix
PA grafting for regenerative surgery. The average age was
72 years (range 64–88 years). All patients were affected by
nonhealing venous ulcers of the lower leg, and all of them
underwent standard-care treatment for 6 weeks consisting
of wound bed preparation according to the TIME algorithm
[14] and a perimetral evaluation of wounds in order to check
for spontaneous tendency to reepithelization. After 4 weeks
of standard care, as the wound did not show any sign of
reepithelization, the patients were enrolled in the protocol
for Hyalomatrix PA grafting. In all cases, Hyalomatrix PA
was grafted to cover the ulcer after wound bed preparation.
Patients were previously treated with a mild local anesthesia
all along the wound’s borders in order to fix the product
with nonabsorbable stitches. Afterwards, the grafted area was
covered with a noncompressive dressing.
The first control visit was carried out after 2 days, while
the change of secondary dressing was performed every 7
days. The silicone film was removed between 18 and 21 days,
and ultra thin (0.1mm) autografts were applied in 12 patients
only after the first Hyalomatrix PA application, unmeshed or
meshed depending on the extension of the surface area. In
fact an epidermal graft overlay is usually necessary after 3
weeks to achieve the in vivo reconstruction of a full thickness
skin equivalent. The patients were systematically reexamined
and submitted to a periodic followup.
3. Results
Thirteen (81, 25%) patients reported an improvement of
wound pain that had already began 3 days after surgery. The
final results were considered to be good in 12 cases, fair in
3 cases, and poor in one case (Table 1). Two patients (no.
8 and no. 11) showed a green exudate through the silicone
layer 5 days after Hyalomatrix PA application; therefore a
microbiological swabwas performed and resulted in a change
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Figure 1: Venous ulcer in 76-year patient (no. 14).
Figure 2: Hyalomatrix PA is put into position and stapled.
of the antibiotic therapy (levofloxacin 500mg once a day
for 10 days instead of amoxicillin/clavulanic acid 3 g/day).
In patient no. 11, the silicone layer had to be removed as it
peeled off. Infection improvement was reached 3 days after
antibiotic therapy change; nevertheless the patient did not
achieve a satisfying healing. On the other hand, patient no.
8 showed a complete recovery from infection resulting in a
quick reepithelization from wound edges.
In all the other patients, a fast reepithelization was
observed, as if each wound had turned from a chronic into
an acute one. In the 14 patients who had no complications, at
the removal of the silicone layer on the 21st day on average, a
clean, reddish wound bed, with reepithelizating borders, was
found.
Four of these patients (nos. 2, 4, 14, and 16) did not require
the epidermal graft since they showed a quick and satisfying
reepithelization from wound’s edges, achieving a complete
healing (Figures 1, 2, and 3). All the other patients required
epidermal graft (Figures 4 and 5). After a 6-month followup,
no recurrences were observed in all patients but one (patient
no. 11), whose lesion never completely closed, although a 70%
reepithelization was reported at the last visit.
4. Discussion
In our experience, the HYAFF-based matrices have been
extremely useful in the healing process of nonhealing ulcers.
Hyalomatrix PA displays advantages including off-the-shelf
Figure 3: Complete reepithelization 45 days after Hyalomatrix PA
graft, without need of epidermal graft.
Figure 4:Meshed skin autograft applied on aHyalomatrix-prepared
wound bed.
availability and user-friendly application technique; more-
over, it contributes to a fast pain reduction and improves the
reepithelization speed with a regenerative mechanism.
Hyaluronic acid is one of the extra cellular matrix
components. Extracellular matrix microenvironment (ECM)
has multiple roles in a living organism, including structural,
mechanical, and trophic functions. ECM allows the exchange
of nutrients andwastes and is the “battlefield” of immune cells
that migrate from the vessels to tissues to destroy pathogens
or to remove the remains of physiological cell turnover.
In addition, ECM can bind signal molecules like growth
factors, mitogens, chemokines, and cytokines, which makes
the tissue microenvironment suitable for cell proliferation,
migration, and differentiation. In vertebrates, the main ECM
polysaccharides are chondroitin sulfates, dermatan sulfates,
heparan sulfates, and keratan sulfates, which represent the
glycosaminoglycans (GAGs) chains of proteoglycans (PGs).
Nevertheless, the most represented GAG in ECM is hyaluro-
nan (HA), a polymer not linked to proteins.
HA is a linear unsulfatedGAG that is composed of repeat-
ing units of D-glucuronic acid and N-acetylglucosamine
linked together through alternating beta-1,4 and beta-1,3
glycosidic bonds. Considering the relative simple chemical
structure of HA, which lacks the structural complexity of
the other GAGs, the only way to introduce information of
biological relevance for HA is the variation of its size. Hence,
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Figure 5: Complete taking of the skin graft after 6 weeks; the excel-
lent dermal matrix quality of the autograft and of the surrounding
skin can be noticed.
the molecular mass strongly influences the effect that HA has
on cells properties [15].
In skin the HA is particularly abundant, the dermis
contains almost 50% of total HA of human body, and the epi-
dermis has a very high pericellular concentration of HA pro-
duced by keratinocytes.The synthesis of HA by keratinocytes
is a specific marker of their differentiation [16]. Skin lesion
is often coupled with HA alterations both in quantity and in
quality.Most agents affecting skin integrity are able to destroy
the HA, and the fragments obtained, oligosaccharides, show
a remarkable proinflammatory effect. The oligosaccharides
are able to exert a strong chemotactic activity promoting the
infiltration of immune cells and angiogenesis. These actions
aremodulated throughout specific cell receptors expressed on
cell membrane, including CD44, RHAMM. Recently it was
suggested that even the TLRs are able to interact with HA
supporting the idea that this polymer could play an important
role in innate immune system [17].
Hyalomatrix PA is made of HYAFF, a derivative of HA.
It is a bilayered, sterile, and flexible wound device that acts
as a regenerative matrix in the treatment of wounds. The
HYAFF wound contact layer affords the advantages provided
by HA in a three-dimensional scaffold, which is colonized by
fibroblasts and ECM components favoring a reconstruction
of the dermal tissue [18].
The silicone film on top of the HYAFF layer guarantees
a barrier function avoiding vapor loss, reducing bacterial
invasion, and allowing for monitoring the wound repair
process.
Moreover, following Hyalomatrix PA degradation, a high
concentration of hyaluronic acid is released at the wound
site. In slow-healing wounds, the high local concentration
of hyaluronic acid released on the site following degra-
dation of HYAFF matrix kick starts the healing process
recreating an acute wound that can progress through the
normal stages of healing. Our clinical cases confirm previous
clinical experience that demonstrated that Hyalomatrix PA
is capable of acting as a bioinductive, hyaluronan-based
dermal substitute that stimulated the healing process [13]
and suggest that the combination of wound bed preparation
with a graft of a hyaluronic regenerative matrix could be
a good approach for treatment of partial thickness ulcers. We
consider Hyalomatrix PA an important tool to achieve the
wound closure in venous ulcers more easily.
Chronic wounds have a significant adverse effect on
patients’ quality of life; therefore ulcer healing is an important
goal that significantly increases patients’ quality of life and
reduces associated costs.
References
[1] V. Falanga andW.H. Eaglstein, “The “trap” hypothesis of venous
ulceration,”The Lancet, vol. 341, no. 8851, pp. 1006–1008, 1993.
[2] S. Takase, L. Pascarella, L. Lerond, J. J. Bergan, and G. W.
Schmid-Scho¨nbein, “Venous hypertension, inflammation and
valve remodeling,” European Journal of Vascular and Endovas-
cular Surgery, vol. 28, no. 5, pp. 484–493, 2004.
[3] M. A. M. Loots, E. N. Lamme, J. Zeegelaar, J. R. Mekkes, J.
D. Bos, and E. Middelkoop, “Differences in cellular infiltrate
and extracellular matrix of chronic diabetic and venous ulcers
versus acute wounds,” Journal of Investigative Dermatology, vol.
111, no. 5, pp. 850–857, 1998.
[4] H. J. Wallace andM. C. Stacey, “Levels of tumor necrosis factor-
𝛼 (TNF-𝛼) and soluble TNF receptors in chronic venous leg
ulcers—correlations to healing status,” Journal of Investigative
Dermatology, vol. 110, no. 3, pp. 292–296, 1998.
[5] R. W. Tarnuzzer and G. S. Schultz, “Biochemical analysis of
acute and chronic wound environments,” Wound Repair and
Regeneration, vol. 4, no. 3, pp. 321–325, 1996.
[6] N. J. Trengove, S. R. Langton, and M. C. Stacey, “Biochemical
analysis of wound fluid from nonhealing and healing chronic
leg ulcers,” Wound Repair and Regeneration, vol. 4, no. 2, pp.
234–239, 1996.
[7] M. V. Mendez, A. Stanley, H.-Y. Park, K. Shon, T. Phillips, and
J. O. Menzoian, “Fibroblasts cultured from venous ulcers dis-
play cellular characteristics of senescence,” Journal of Vascular
Surgery, vol. 28, no. 5, pp. 876–883, 1998.
[8] R. J. Snyder, “Treatment of nonhealing ulcers with allografts,”
Clinics in Dermatology, vol. 23, no. 4, pp. 388–395, 2005.
[9] W. Y. J. Chen and G. Abatangelo, “Functions of hyaluronan in
wound repair,”Wound Repair and Regeneration, vol. 7, no. 2, pp.
79–89, 1999.
[10] K. Harding, Clinical Challenges and Promises of HYAFF Tech-
nology in Wound Healing Redefining Hyaluronan, Elsevier BV,
2000.
[11] R. D. Price, V. Das-Gupta, I. M. Leigh, and H. A. Navsaria,
“A comparison of tissue-engineered hyaluronic acid dermal
matrices in a human wound model,” Tissue Engineering, vol. 12,
no. 10, pp. 2985–2995, 2006.
[12] G. Gravante, D. Delogu, N. Giordan, G. Morano, A. Montone,
and G. Esposito, “The use of hyalomatrix PA in the treatment
of deep partial-thickness burns,” Journal of Burn Care and
Research, vol. 28, no. 2, pp. 269–274, 2007.
[13] C. Caravaggi, F. Grigoletto, and N. Scuderi, “Wound bed
preparation with a dermal substitute (hyalomatrix PA) facili-
tates re-epithelialization and healing: results of a multicenter,
prospective, observational study on complex chronic ulcers (the
FAST study),”Wounds, vol. 23, no. 8, pp. 228–235, 2011.
[14] C. Dowsett and E. Ayello, “TIME principles of chronic wound
bed preparation and treatment,” British Journal of Nursing, vol.
13, no. 15, pp. S16–23, 2004.
BioMed Research International 5
[15] A. Asari, “Novel Functions of Hyaluronan Oligosaccharides,”
Science of Hyaluronan Today, February 2005, http://www.gly-
coforum.gr.jp/science/hyaluronan/hyaluronanE.html.
[16] A. Passi, P. Sadeghi, H. Kawamura et al., “Hyaluronan sup-
presses epidermal differentiation in organotypic cultures of rat
keratinocytes,” Experimental Cell Research, vol. 296, no. 2, pp.
123–134, 2004.
[17] D. Jiang, J. Liang, and P. W. Noble, “Hyaluronan as an immune
regulator in human diseases,” Physiological Reviews, vol. 91, no.
1, pp. 221–264, 2011.
[18] G. Galassi, P. Brun, M. Radice et al., “In vitro reconstructed
dermis implanted in human wounds: degradation studies of the
HA-based supporting scaffold,” Biomaterials, vol. 21, no. 21, pp.
2183–2191, 2000.










Hindawi Publishing Corporation 
http://www.hindawi.com














Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
